Correlation of PET and AMS analyses for early kinetics of 2-fluoro-2-deoxyglucose (FDG)

Abstract The draft of the guidelines for microdosing in clinical trials was published in Japan in 2008 following the guidelines of the European Medicines Agency (EMEA) and the Food and Drug Administration (FDA). It recommends utilizing accelerator mass spectrometry (AMS), liquid chromatography/mass spectrometry (LC/MS/MS), and positron emission tomography (PET) for monitoring drug metabolites in preclinical studies. In this study, we clarified the correlation in measuring result between PET and AMS. The AMS measurement was undergone by using AMS system of Institute of Accelerator Analysis Ltd. (IAA, Kawasaki, Japan). First the back ground 14 C level of blood in mice was measured by AMS. Second, we clarified the relationship between AMS and PET by using 2-fluoro-2-deoxyglucose (FDG). The correlation coefficient ( r ) of the measurements using PET ( 18 F-FDG) and AMS ( 14 C-FDG) were quite high at 0.97 ( Y  = 7.54 E  − 05 X  + 0.02, p 18 F-FDG was nearly identical with that of 14 C-FDG. These results indicate that the AMS analysis has excellent correlation with the PET method.